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Accepted 16 July 2014Mycophenolate mofetil (MMF) is a noncytotoxic immu-
nosuppressive, widely used in organ and hematopoietic cell
transplantation (HCT). MMF is selective in its suppression of
lymphocytes rather than myeloid cells, resulting in a more
favorable toxicity proﬁle, which enables faster engraftment
and less cytotoxicity, speciﬁcally mucositis, and is often the
preferred graft-versus-host disease (GVHD) prophylaxis in
allogeneic HCT, particularly with reduced-intensity condi-
tioning. Al-Kadhimi et al. recently report on their experience
with MMF and tacrolimus for GVHD prophylaxis in a large
cohort of patients undergoing HCT [1]. They deserve
commendation for reporting the largest cohort of patients to
date treated with a uniform MMF-based GVHD prevention
regimen in allogeneic HCT.
However, they report an unacceptably high incidence of
severe (grade III and IV) acute GVHD in both sibling donor
and unrelated donor cohorts (22.3% and 36.5%, respectively).
A recent Center for International Blood and Marrow Trans-
plant Research study has also raised a question of efﬁcacy
with MMF as GVHD prophylaxis in reduced-intensity unre-
lated donor transplantations, with a signiﬁcantly higher
likelihood of developing acute GVHD using MMF compared
withmethotrexate-based GVHD regimens [2]. In contrast, we
previously presented, in abstract form, our retrospective
experience with MMF in myeloablative sibling donor trans-
plantations (n¼ 114), with an incidence of grade II to IV acute
GVHD of 34% and severe grades III and IV GVHD of 12%, and
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http://dx.doi.org/10.1016/j.bbmt.2014.07.023deaths were attributed to acute and chronic GVHD, respec-
tively [3], compared with the 49% of deaths related to GVHD
reported in Al-Kadhimi’s study [1].
We suspect higher-intensity conditioning and the inclu-
sion ofmismatched unrelated donorsmay have contributed to
the higher incidence of severe acute GVHD in the Al-Kadhimi
study [1]. Yet, there remain many conﬂicting and unresolved
issues regarding the use of MMF as GVHD prophylaxis, and
there are several points that must be further raised and
highlighted. The interindividual variation of plasma levels of
mycophenolic acid (MPA) (the active form of MMF) as well as
the dosing and duration of MMF are important factors to be
further considered and optimized. Al-Kadhimi et al. used a
relatively low dose of MMF compared with the 10 mg/kg
every 8 hours (30 mg/kg daily) dosing that is now more
widely used. Several other studies have suggested that higher
dosing improves outcomes and leads to signiﬁcantly
decreased severe acute GVHD. Nash et al. suggested a dose of
45 mg/kg/day as the optimal dose, with an incidence of grade
II to IV GVHD of 36% [4]. Furthermore, pharmacokinetic
studies of MMF used for GVHD treatment demonstrate that
the concentration ofMPA is signiﬁcantly greater in responders
compared with nonresponders [5]. The correlation between
pharmacokinetics and efﬁcacy in the prevention of GVHD has
not been as well elucidated, but previous studies have
demonstrated that patients with lower MPA steady-state
concentrations had increased GVHD, compared with those
with higher levels, especially in unrelated donors [6,7]. In
addition, a recently reported study in umbilical cord trans-
plantation has demonstrated the superiority of a higher MMF
dose (3000 mg/day compared with 2000 mg/day) for the
prevention of acute GVHD, with otherwise similar infectious,
relapse, and survival outcomes [8].
Duration of MMF is also likely to play an important role,
and Al-Kadhimi report the withdrawal of MMF at day þ30
without taper. Although the optimal duration of MMF after
transplantation has not been well established, there are
several studies that employ a prolonged course of MMF, with
or without taper to day þ50, or longer, as is the practice at
our institution, with low incidences of reported GVHD and
nonrelapse mortality [9,10]. Nishikawa et al. reported the
Letters to the Editor / Biol Blood Marrow Transplant 20 (2014) 1869e18711870only study we are aware of that compared different dura-
tions of MMF. They demonstrated a signiﬁcant decrease in
grade II to IV GVHD in a small cohort of patients who
received extended administration; this study may provide
preliminary evidence of the potential differences in a longer
course of MMF [10].
MMF remains a well-tolerated and important immuno-
suppressive agent in our already limited arsenal of GVHD
prevention. Although newer and alternative GVHD prophy-
laxis regimens are certainly needed, the use of MMF should
not be abandoned until the optimal dosing and duration is
studied in larger prospective trials.
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We read with interest the report by Showel et al. [1] and
commentary by Gerber [2] describing the lack of a correla-
tion in some people between isolated clonal cytogenetic
abnormalities after autotransplant and leukemia recurrence.
The authors reasonably speculated this might be because
most subjects lacked abnormalities such as del(5/5q) or
del(7/7q), which alone might have been sufﬁcient to cause
acute myelogenous leukemia, because the clonalabnormalities occurred in only a fewmetaphases, suggesting
no proliferative advantage for the new clone and/or because
of brief follow-up.
The issue arises whether their observation applies only
to isolated clonal cytogenetic abnormalities or is a more
general phenomenon. We and others reported diverse
oligo- and polyclonal abnormalities in autotransplant
hrecipients, sometimes accompanied by nonclonal abnor-
malities, especially indels and aneuploidy. New trans-
locations are especially favored when ionizing radiation is
given pretransplant because of the tendency of photons to
cause synchronous and contiguous double-strand breaks in
interphase cells. These abnormalities can represent a sub-
stantial proportion of metaphases in some instances and
appear to wax and wane over many years, even decades.
Sometimes this is an illusion resulting from imperfect
sensitivity of our detection techniques. A study of 20
metaphases has a substantial likelihood of missing an
abnormality present in 5% to 10% of cells, for example. Also,
conventional cytogenetics capture only dividing cells;
ﬂorescence in situ hybridization can reduce this bias.
Sometimes these complex cytogenetic abnormities are a
harbinger of leukemia recurrence, although they may seem
